Copanlisib抑制磷脂酰肌醇3-激酶治疗复发或难治性惰性淋巴瘤
这项II期研究纳入142例既往≥2线治疗后复发或难治性惰性淋巴瘤患者,接受copanlisib 60 mg静脉给药(28天周期第1、8、15天)。客观缓解率59%(84/142),完全缓解率12%,中位缓解持续时间22.6个月,中位无进展生存期11.2个月,中位总生存未达到。最常见治疗中出现的不良事件为一过性高血糖(全部级别50%,3或4级41%)和一过性高血压(全部级别30%,3级24%)。
要点
- 复发或难治性惰性淋巴瘤患者客观缓解率59%(84/142),完全缓解率12%。
- 中位缓解持续时间22.6个月,中位无进展生存期11.2个月,中位总生存未达到。
- 常见不良事件为一过性高血糖(全部级别50%,3或4级41%)和一过性高血压(全部级别30%,3级24%)。
核心结论
- Copanlisib抑制PI3K-α和-δ在重度经治的复发或难治性惰性淋巴瘤患者中显示出显著疗效和可控的安全性。
研究设计与样本
- II期研究,纳入142例既往接受≥2线治疗后复发或难治性惰性淋巴瘤患者。
- 给药方案为copanlisib 60 mg静脉给药,28天周期第1、8、15天。
- 主要终点为客观缓解率;次要终点包括缓解持续时间、无进展生存期和总生存,并评估安全性和基因表达。
主要发现
- 中位年龄63岁(范围25至82岁),既往中位治疗线数3线(范围2至9线)。
- 客观缓解率59%(84/142),12%的患者达到完全缓解。
- 中位起效时间53天,中位缓解持续时间22.6个月,中位无进展生存期11.2个月,中位总生存未达到。
- 最常见治疗中出现的不良事件为一过性高血糖(全部级别50%;3或4级41%)和一过性高血压(全部级别30%;3级24%)。
- 其他≥3级事件包括中性粒细胞计数降低(24%)和肺部感染(15%);对copanlisib的高缓解率与PI3K/B细胞受体信号通路基因高表达相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant activity against PI3K-α and -δ isoforms, has demonstrated efficacy and a manageable safety profile in patients with indolent lymphoma. Patients and Methods In this phase II study, 142 patients with relapsed or refractory indolent lymphoma after two or more lines of therapy were enrolled to receive copanlisib 60 mg intravenously on days 1, 8, and 15 of a 28-day cycle. The primary end point was objective response rate; secondary end points included duration of response, progression-free survival, and overall survival. In addition, safety and gene expression were evaluated. Results Median age was 63 years (range, 25 to 82 years), and patients had received a median of three (range, two to nine) prior regimens. The objective response rate was 59% (84 of 142 patients); 12% of patients achieved a complete response. Median time to response was 53 days. Median duration of response was 22.6 months, median progression-free survival was 11.2 months, and median overall survival had not yet been reached. The most frequent treatment-emergent adverse events were transient hyperglycemia (all grades, 50%; grade 3 or 4, 41%) and transient hypertension (all grades, 30%; grade 3, 24%). Other grade ≥3 events included decreased neutrophil count (24%) and lung infection (15%). High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes. Conclusion PI3K-α and -δ inhibition by copanlisib demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.
引用
- Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017. PMID: 28976790. doi:10.1200/JCO.2017.75.4648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。